Please login to the form below

Not currently logged in
Email:
Password:

FDA rules on children's cough medicines

The FDA has said that cough medicines should not be given to children aged under two years, unless approved by a doctor

The FDA has said that cough medicines should not be given to children aged under two years, unless approved by a doctor.

The ruling is the first major reassessment of the safety of children's cough and cold medicine for over ten years. Additional warnings about the drugs may materialise, because the FDA revealed it would be meeting with a panel of independent experts on 18 October.

It is anticipated that the experts will advise the agency about how new label warnings or prohibitions should be implemented. The panel will also discuss the ways in which parents and caregivers administer the drugs to children.

In high enough doses, cold medicines affect the beat of the heart and cause arrhythmia. Also, other types of cold and flu medicines constrict blood vessels. The medicines have been associated with high blood pressure, strokes and injury in cases where a child has been over-medicated.

The FDA has ruled that children should never be given cough and cold medicines which have been packaged for adults. The agency further advised that parents should closely follow label directions about the appropriate dose to give their children.

In March 2007, a group of paediatricians and public health officials petitioned the FDA to remove medicines intended for children under the age of six. The petition stated that the medicines did not work and could result in serious injury in rare cases.

The medicines under review include Toddler's Dimetapp, Infant Triaminic and Little Cold. Many of the active ingredients in these products have never undergone safety reviews by the FDA.

16th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics